|
⚲
|
| Keyboard |
| GoldenTree Asset Management LP
✚
|
|
|---|---|
| CRD # | 112753 |
| SEC # | 801-58286 |
| CIK # | 0001435627, 0001278951 |
| AUM | 70.14 B (2026-06-11) |
| Employees | 320 (25% Investors, 0% Brokers) |
| Fees | |
| Minimum | |
| Phone | 212-847-3500 |
| Address | 300 Park Avenue New York, NY 10022 |
| Source | [IAPD] [EDGAR] [Website] |
| Total AUM ($B) |
|---|
| In the News | |
|---|---|
| Thu, 02 Jul 2026 | GoldenTree Asset Management Closes $726MM CLO Under GLM Strategy — ABF Journal |
| Fri, 26 Jun 2026 | GoldenTree Asset Management Announces Closing of $726 Million CLO Under GLM Strategy — Business Wire |
| Thu, 14 May 2026 | GoldenTree Asset Management Closes $602MM CLO Under GLM Strategy — ABF Journal |
| Wed, 13 May 2026 | GoldenTree Asset Management: $602 Million CLO Expands GLM Strategy To More Than $21 Billion — Pulse 2.0 |
| Wed, 15 Apr 2026 | GoldenTree Asset Management Hires Ken Takao as Head of Business Development in Japan — citybiz |
| Fees and Compensation — Form ADV Part 2A (3/31/2026) [Brochure] |
|---|
Item 5 Fees and Compensation Clients are typically charged a management fee that is generally based on the net asset value (“NAV”) of the assets under management at a negotiated rate depending upon the type of fund or account managed and strategy. With respect to certain close-ended Funds and separately managed accounts with private equity-like terms, management fees may be based on funded commitments to such funds or NAV. For CLOs managed by GoldenTree, the management fee will be based on the aggregate deal size or the amount of assets managed taking into account the effects of leverage. Certain Clients will also be charged an annual performance fee depending upon the investment mandate. In such cases, the negotiated performance fee will be based on net capital appreciation at the end of a fiscal year for GoldenTree’s evergreen alternative offerings and realized gains for close-ended funds and separately managed accounts with private equity-like terms (after generally the return to investors in such private equity funds of their contributed capital or the liquidation of investment assets to the extent of net gains, and the Client achieving a certain preferred return). With respect to certain Funds, performance fees may be charged on distributions made to a limited partner, subject to: (1) the return of a limited partner’s capital contributions in respect of investments (including investments that were written down or written off and related fees and expenses) and (2) a preferred rate of return on a limited partner’s capital contributions. In the event of an over assessment of performance fees, the performance fee recipient is generally subject to an after-tax “claw back” arrangement to ensure the performance fees remain consistent with the Funds’ offering documents. The specific payment terms and other conditions of the performance fee are described in further detail in the Funds’ offering documents. With respect to our evergreen alternative offerings (in Fund and separately managed account format), losses typically will be carried forward from year-to-year, depending on the Client’s terms and conditions, so that no performance fee is charged unless some or all of such losses incurred through the end of the period for which the fee is to be paid (or made) have been recouped (such an arrangement being called a high water mark provision). Certain Funds (and separately managed accounts that allow for a performance fee to be charged) may also have a preferred rate of return that must be met prior to a performance fee being assessed. The annual management fee is calculated and assessed at the beginning or end of each quarter depending upon the Client. Withdrawing investors from a Fund or Clients that terminate investment advisory services before the end of a billing period are generally refunded any prepaid fees in excess of those applicable to the period of actual investment. With respect to separately managed accounts, fee arrangements are negotiated prior to the engagement of GoldenTree as an investment manager. In regard to Funds, the respective offering documents will disclose the fee arrangements associated with the different share classes offered to investors. A Fund’s offering documents generally permit GoldenTree or such Fund to waive, rebate, or reduce all or part of the management fee and/or performance fee with respect to investments made by certain investors without waiving, rebating or reducing the fees charged/payable to other investors (such as in the case of, but not limited to, investments in such Fund made by GoldenTree, its partners/employees and their family members, or co-invest accounts and vehicles). In addition, in certain cases GoldenTree, as the “Investment Manager”, will have the discretion to grant special or more favorable rights, without limitation, with respect to fees, transfers, notices and transparency. Such rights may be granted to any Fund investor, including, without limitation, principals, members or employees (and their respective family members) of GoldenTree and its affiliates and other select third parties. To effect such waivers or modifications or to grant any special or more favorable rights, the Fund will generally enter into agreements (such as "Side Letters") or issue other classes of shares. Depending upon the Client and the authority granted to GoldenTree, GoldenTree will deduct its fees from the Client based on the terms of the investment management agreement or offering documents. Generally, separately managed accounts and CLOs will be billed and will authorize payment to GoldenTree. For example, in the case of a CLO, payment is made through an independent trustee signing-off on the expenses. If received in connection with investments, fees such as break-up fees, director fees, etc. will be remitted to Clients (or a fee/expense offset will occur that will equal such break-up fees, directors fees, etc.). GoldenTree will not retain any such fees. GoldenTree and/or its affiliates may receive fees, other compensation (including management fees) or reimbursements for internal and external costs or expenses in connection with the provision of portfolio management, asset management and operational support in connection with asset management and/or investment advisory services (collectively, "Portfolio Management Services") to portfolio companies that are owned by Clients in their managed accounts. No such fees, compensation or reimbursements for costs or expenses will be paid to the Clients (or offset against, or otherwise be applied to reduce, the management fee) provided that any such fees or other compensation paid to GoldenTree and/or its affiliates by such portfolio companies will be charged at rates no less favorable to such portfolio companies than the rates charged by a third party provider of the applicable services in arms' length transactions. ... |
| Sector | Form 13F Holdings | Value ($B) | |
|---|---|---|---|
| Biovail Corp | 0.2 | ||
| Comcast Corp | 0.2 | ||
| MGM Resorts International | 0.2 | ||
| Waystar Holding Corp | 0.1 | ||
| CB Richard Ellis Group Inc | 0.1 | ||
| Norwegian Cruise Line Holdings Ltd | 0.1 | ||
| Jazz Pharmaceuticals Inc | 0.1 | ||
| Ally Financial Inc | 0.1 | ||
| Elastic NV | 0.1 | ||
| SeaWorld Entertainment Inc | 0.1 | ||
| View All | |||
| Holdings by Sector ($B) |
|---|
| Type | Form D Funds | Date | Sold | AUM |
|---|---|---|---|---|
| SA | GoldenTree Loan Management US CLO 26 Ltd | 2026-06-11 | 500.0 M | |
| SA | GoldenTree Loan Management US CLO 27 Ltd | 2026-06-11 | 750.0 M | |
| HF | GoldenTree Multi Sector Opportunistic Master Fund Ltd | 2026-03-30 | 1,029.6 M | |
| SA | GoldenTree Loan Management US CLO 24 Ltd | 2026-01-06 | 522.8 M | |
| SA | GoldenTree Loan Management US CLO 25 Ltd | 2026-01-06 | 367.2 M | |
| SA | GoldenTree Loan Management EUR CLO 10 Designated Activity Company | 2025-06-02 | 400.0 M | |
| HF | GoldenTree Multi Sector Custom Fund I LP | 2025-03-28 | 911.0 M | |
| HF | GoldenTree Private Credit Master Fund II LP | [2025-03-28] | 210.8 M | 1,849.5 M |
| Filed 2025-12-23 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration More than one year · Commission $10,625 · Revenue Decline to Disclose | ||||
| HF | GoldenTree Tactical Opportunities Master Fund I LP | 2025-02-26 | 3,118.9 M | |
| SA | GoldenTree Loan Management EUR CLO 7 Designated Activity Company | 2025-02-13 | 494.7 M | |
| View All | ||||
| AUM Breakdown | Accounts | AUM ($B) |
|---|---|---|
| By Client Type | ||
| (a) Individuals (other than high net worth individuals) | 0 | 0.0 |
| (b) Individuals (high net worth individuals) | 0 | 0.0 |
| (c) Banking or thrift institutions | 0 | 0.0 |
| (d) Investment companies | 0 | 0.0 |
| (e) Business development companies | 0 | 0.0 |
| (f) Pooled investment vehicles | 91 | 49.1 |
| (g) Pension and profit sharing plans | 10 | 2.7 |
| (h) Charitable organizations | 0 | 0.0 |
| (i) State or municipal government entities | 10 | 5.0 |
| (j) Other investment advisers | 0 | 0.0 |
| (k) Insurance companies | 7 | 1.3 |
| (l) Sovereign wealth funds and foreign official institutions | 0 | 0.0 |
| (m) Corporations or other businesses not listed above | 43 | 12.0 |
| (n) Other | 0 | 0.0 |
| Total | 161 | 70.1 |
| By Discretionary | ||
| Discretionary | 161 | 70.1 |
| Non-Discretionary | 0 | 0.0 |
| Total | 161 | 70.1 |
| By Non-United States Persons | ||
| Non-United States Persons | 59.6 | |
| United States Persons | 10.6 | |
| Total | 161 | 70.1 |
| Form D Directors | Role | # Filings | # Firms | 2011 - 2026 |
|---|---|---|---|---|
| Michelle Wilson-Clarke | Director | 284 | 70 | |
| Scott Lennon | Director | 163 | 37 | |
| Christopher Bowring | Director | 177 | 35 | |
| Abali Hoilett | Director | 137 | 35 | |
| Tim Woolaver | Director | 90 | 25 | |
| Robert Meschi | Director | 145 | 22 | |
| Martin Byrne | Director | 130 | 21 | |
| Deanna Derrick | Director | 40 | 15 | |
| Alison Martinson | Director | 38 | 13 | |
| George Travers | Director | 49 | 5 | |
| View All | ||||
| EDGAR Form | CIK | 2011 - 2026 |
|---|---|---|
| 13F-HR | [0001278951] | |
| 3 | [0001278951] | |
| 4 | [0001278951] | |
| SC 13D | [0001278951] | |
| SC 13G | [0001278951] | |
| 3 | [0001435627] | |
| 4 | [0001435627] |
| Firm Profile (Form ADV) | |
|---|---|
| Discretionary AUM | $22.0B |
| Serves | Institutional |
| Fund Types | Hedge Fund |
| LEI | PUBZ8X9O2VZN0WHEH824 |
| Insider Transaction (Form 3/4/5) | Date | Action | Shares | Price | Value ($) |
|---|---|---|---|---|---|
|
GoldenTree Opportunistic Credit Fund NONE
Class I Shares of Beneficial Interest
|
2026-02-13 | Buy | 971,817.30 | $10.29 | 10,000,000 |
|
GoldenTree Opportunistic Credit Fund NONE
Class I Shares of Beneficial Interest
|
2025-11-28 | Buy | 1,949,317.74 | $10.26 | 20,000,000 |
|
GoldenTree Opportunistic Credit Fund NONE
Class I Shares of Beneficial Interest
|
2025-08-11 | Buy | 1,492,537.31 | $10.05 | 15,000,000 |
|
GoldenTree Opportunistic Credit Fund NONE
Class I Shares of Beneficial Interest
|
2025-08-07 | Buy | 1,494,023.90 | $10.04 | 15,000,000 |
|
Keenova Therapeutics PLC NONE
Ordinary Shares
|
2025-08-06 | Buy | 6,700 | $92.50 | 619,750 |
|
Keenova Therapeutics PLC NONE
Ordinary Shares
|
2025-08-04 | Buy | 30,000 | $87.25 | 2,617,500 |
|
Keenova Therapeutics PLC NONE
Ordinary Shares
|
2025-08-01 | Buy | 50,000 | $86.50 | 4,325,000 |
|
Keenova Therapeutics PLC NONE
Ordinary Shares
|
2025-07-31 | Other | 4,539,148 | ||
|
Keenova Therapeutics PLC NONE
Ordinary Shares
|
2025-07-31 | Other | 33,651 | ||
|
Keenova Therapeutics PLC MNKTQ
Ordinary Shares
|
2024-07-08 | Buy | 13,300 | $54.50 | 724,850 |
|
Keenova Therapeutics PLC MNKTQ
Ordinary Shares
|
2024-06-14 | Buy | 275,000 | $52.75 | 14,506,250 |
|
Keenova Therapeutics PLC MNKTQ
Ordinary Shares
|
2024-05-24 | Buy | 165,000 | $50.00 | 8,250,000 |
|
Keenova Therapeutics PLC MNKTQ
Ordinary Shares
|
2024-05-09 | Buy | 350,000 | $55.50 | 19,425,000 |
|
Keenova Therapeutics PLC MNKTQ
Ordinary Shares
|
2024-05-09 | Buy | 125,000 | $55.00 | 6,875,000 |
|
Keenova Therapeutics PLC MNKTQ
Ordinary Shares
|
2024-03-08 | Buy | 83,000 | $43.63 | 3,621,290 |
|
Keenova Therapeutics PLC MNKTQ
Ordinary Shares
|
2024-02-15 | Buy | 225,000 | $38.25 | 8,606,250 |
|
Keenova Therapeutics PLC MNKTQ
Ordinary Shares
|
2024-02-02 | Buy | 20,000 | $37.55 | 751,000 |
|
Keenova Therapeutics PLC MNKTQ
Ordinary Shares
|
2023-12-05 | Buy | 75,000 | $37.50 | 2,812,500 |
|
California Resources Corp CRC
Common Stock
|
2022-04-06 | Sell | 29,302 | $44.07 | 1,291,339 |
|
California Resources Corp CRC
Common Stock
|
2022-04-05 | Sell | 90,000 | $43.99 | 3,959,100 |
| showing 20 of 200 most recent transactions | |||||
| Comparable Firms | State | AUM |
|---|---|---|
|
Two Sigma Advisers LP
✚
|
NY | 74.26 B |
|
Caxton Associates LLP
✚
|
71.56 B | |
|
Adage Capital Management LP
✚
|
MA | 70.44 B |
|
BlackRock Singapore Limited
✚
|
70.33 B | |
|
Fulcrum Asset Management LLP
✚
|
69.09 B | |
|
Russell Investment Management LLC
✚
|
WA | 68.60 B |
|
Jupiter Asset Management Limited
✚
|
68.22 B | |
|
AHL Partners LLP
✚
|
68.02 B | |
|
Walter Scott & Partners Limited
✚
|
66.67 B | |
|
GLG Partners LP
✚
|
64.51 B |